The keys to the oncology ward

Pinsonault, Tony
September 2008
Pharmaceutical Representative;Sep2008, Vol. 38 Issue 9, p26
The article reports on the growing oncology market worldwide. It states that the global sales of oncology products are expected to grow at a compounded annual rate of 12% to 15% by 2012, reaching nearly $80 billion. It adds that the said growth is rich in opportunities for pharmaceutical and biotech companies and for representatives with knowledge of product-specific clinical protocols and reimbursement policies.


Related Articles

  • Outsourcing in Drug Development. Clemens, Norbert // Drug Development;2010, Vol. 5, p48 

    The cost of drug development has soared during recent decades, compelling pharmaceutical and biotechnology companies to look for different ways of conducting clinical research. Driven by market pressures, companies have implemented outsourcing strategies to increase revenues through faster drug...

  • Protocol Amendments: A Costly Solution. Getz, Kenneth A. // Applied Clinical Trials;May2011, Vol. 20 Issue 5, p28 

    The article offers insights on the cost needed to enforce protocol amendments for clinical trials in the U.S. It mentions the use of benchmarking for incidence and effect of protocol amendments in mid-sized to large pharmaceutical and biotechnology companies. It highlights cardiovascular and...

  • Radiolabeled Peptides in Oncology: Role in Diagnosis and Treatment. Weiner, Ronald E.; Thakur, Mathew L. // BioDrugs;2005, Vol. 19 Issue 3, p145 

    There has been an exponential growth in the development of radiolabeled peptides for diagnostic and therapeutic applications in the last decade. The automated means of synthesizing these compounds in large quantities and the simplified methods of purifying, characterizing, and optimizing them...

  • Effecting a comprehensive intellectual property strategy using the Madrid Protocol. Simmons, William J. // Nature Biotechnology;May2004, Vol. 22 Issue 5, p603 

    To assist in the global effort to streamline trademark registration, the United States recently joined over 60 other countries in adopting the Madrid Protocol. This article discusses the significance of trademarks in the biotech and pharmaceutical industries, and describes how companies can use...

  • PR View. McDade, Paul // Medical Marketing & Media;Oct2003, Vol. 38 Issue 10, p30 

    Focuses on the expected emergence of more than 150 biotechnology drugs. Comparison of the cost of biologic drug and traditional pharmaceuticals; Role of public relations professionals in safeguarding clients' position by encouraging transparency and partnership between biotechs and healthcare...

  • Specialty pharmaceuticals require payers' attention. Brill, Joel V.; Robbins, Dennis // Managed Healthcare Executive;Mar2006, Vol. 16 Issue 3, p58 

    The article reports on the use of advanced specialty pharmaceuticals to treat various medical conditions but they require close clinical monitoring. They need special handling and timely distribution due to their relatively short shelf life and limited stability. Medical policies and clinical...

  • The recovery mission -- coping with validation failures. Krause, Stephan // Pharmaceutical Technology Europe;May2008, Vol. 20 Issue 5, p50 

    The article discusses the recovery process for failed analytical method validation (AMV) to stimulate the development of regulatory guidance. It notes that a validation failure differs from a validation discrepancy as it results from failing to pass acceptance criteria. It further notes that in...

  • Containment-Verification Testing For Pharmaceutical Equipment Performance. Petroka, George S. // Pharmaceutical Technology;May2013 Supplement, ps24 

    The article offers information on the containment-verification testing program to evaluate the performance of pharmaceutical equipments containing hazardous Active Pharmaceutical Ingredients (APIs). It further mentions that selection of containment include process review and containment...

  • Consultation documents.  // WHO Drug Information;2014, Vol. 28 Issue 3, p343 

    The article presents the revised draft proposal for a new medicines and quality assurance guideline Working document QAS/13.52/Rev.3, August 2014. Topics discussed include an overview of how manufacturers should ensure the safety, effectiveness and quality of their products, a glossary of terms,...


Read the Article


Sign out of this library

Other Topics